Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma

Abstract

Du Jiahang, Chen Dong, Chen Yaoting. Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2021, 48(9): 572-.

References25

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492
[2]	Jeong SO, Kim EB, Jeong SW, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma[J]. Gut Liver, 2017, 11(3):409-416. DOI: 10.5009/gnl16001. doi:10.5009/gnl16001pmid:28208001
[3]	Jiang F, Li Y, Si L, et al. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells[J]. Cell Biol Toxicol, 2019, 35(4):361-371. DOI: 10.1007/s10565-018-09458-0. doi:10.1007/s10565-018-09458-0pmid:30612216
[4]	Li X, Sun D, Zhao T, et al. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression[J]. Eur J Pharmacol, 2020, 872:172982. DOI: 10.1016/j.ejphar.2020.172982. doi:10.1016/j.ejphar.2020.172982
[5]	Cai X, Yu L, Chen Z, et al. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1[J]. Cancer Biomark, 2020, 28(2):221-230. DOI: 10.3233/CBM-190490. doi:10.3233/CBM-190490
[6]	Wang HY, Zhang B, Zhou JN, et al. Arsenic trioxide inhibits liver can-cer stem cells and metastasis by targeting SRF/MCM7 complex[J]. Cell Death Dis, 2019, 10(6):453. DOI: 10.1038/s41419-019-1676-0. doi:10.1038/s41419-019-1676-0
[7]	Sun Z, Li M, Bai L, et al. Arsenic trioxide inhibits angiogenesis in vitro and in vivo by upregulating FoxO3a[J]. Toxicol Lett, 2019, 315:1-8. DOI: 10.1016/j.toxlet.2019.08.009. doi:10.1016/j.toxlet.2019.08.009
[8]	Duan X, Li H, Han X, et al. Antitumor properties of arsenic trioxide-loaded CalliSpheres^®microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival[J]. Am J Transl Res, 2020, 12(9):5511-5524.
[9]	Wang Y, Jiang F, Jiao K, et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties[J]. Exp Cell Res, 2020, 386(2):111739. DOI: 10.1016/j.yexcr.2019.111739. doi:10.1016/j.yexcr.2019.111739
[10]	陈耀庭, 胡晓俊, 李丹, 等. 肝细胞癌对三氧化二砷的化疗耐药性机制[J]. 国际肿瘤学杂志, 2016, 43(11):861-864. DOI: 10.3760/cma.j.issn.1673-422X.2016.11.016. doi:10.3760/cma.j.issn.1673-422X.2016.11.016
[11]	Liu H, Zhang Z, Chi X, et al. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells[J]. Sci Rep, 2016, 6:31009. DOI: 10.1038/srep31009. doi:10.1038/srep31009
[12]	Huang Y, Zhou B, Luo H, et al. ZnAs@SiO₂nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling[J]. Theranostics, 2019, 9(15):4391-4408. DOI: 10.7150/thno.32462. doi:10.7150/thno.32462
[13]	Chi X, Zhang R, Zhao T, et al. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma[J]. Nanotechnology, 2019, 30(17):175101. DOI: 10.1088/1361-6528/aaff9e. doi:10.1088/1361-6528/aaff9e
[14]	季峻松, 陈婷, 王辉, 等. 肝动脉化疗栓塞联合灌注三氧化二砷治疗原发性肝癌[J]. 实用医学杂志, 2018, 34(2):251-253. DOI: 10.3969/j.issn.1006-5725.2018.02.023. doi:10.3969/j.issn.1006-5725.2018.02.023
[15]	Yang H, Zhou S, Shen R, et al. Evaluation on efficacy and safety of arsenic trioxide plus transcatheter arterial chemoembolization versus transcatheter arterial chemoembolization alone for unresectable primary liver cancer[J]. Asian Pac J Cancer Prev, 2017, 18(10):2695-2701. DOI: 10.22034/APJCP.2017.18.10.2695. doi:10.22034/APJCP.2017.18.10.2695
[16]	Li H, Wu F, Duan M, et al. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety[J]. Medicine (Baltimore), 2019, 98(21):e15314. DOI: 10.1097/MD.0000000000015314. doi:10.1097/MD.0000000000015314
[17]	Duan XH, Li H, Ren JZ, et al. Hepatic arterial chemoembolization with arsenic trioxide eluting CalliSpheres microspheres versus lipiodol emulsion: pharmacokinetics and intratumoral concentration in a rabbit liver tumor model[J]. Cancer Manag Res, 2019, 11:9979-9988. DOI: 10.2147/CMAR.S199188. doi:10.2147/CMAR.S199188
[18]	Kong D, Jiang T, Liu J, et al. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal[J]. Drug Deliv, 2020, 27(1):1729-1740. DOI: 10.1080/10717544.2020.1856219. doi:10.1080/10717544.2020.1856219
[19]	Li D, Wei Y, Xu S, et al. A systematic review and meta-analysis of bidirectional effect of arsenic on ERK signaling pathway[J]. Mol Med Rep, 2018, 17(3):4422-4432. DOI: 10.3892/mmr.2018.8383. doi:10.3892/mmr.2018.8383
[20]	Wang L, Min Z, Wang X, et al. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand[J]. Oncol Lett, 2018, 16(3):3341-3350. DOI: 10.3892/ol.2018.8981. doi:10.3892/ol.2018.8981
[21]	陈洁盈, 陈耀庭, 林泽宇, 等. 三氧化二砷逆转低浓度索拉非尼对人肝癌细胞促迁移作用及其机制[J]. 中华肝脏外科手术学电子杂志, 2016, 5(2):114-118. DOI: 10.3877/cma.j.issn.2095-3232.2016.02.012. doi:10.3877/cma.j.issn.2095-3232.2016.02.012
[22]	邬德东, 史继静, 张倩, 等. 索拉非尼联合三氧化二砷治疗晚期原发性肝癌的临床研究[J]. 现代肿瘤医学, 2019, 27(15):2728-2731. DOI: 10.3969/j.issn.1672-4992.2019.15.025. doi:10.3969/j.issn.1672-4992.2019.15.025
[23]	Kojima-Yuasa A, Huang X, Matsui-Yuasa I. Synergistic anticancer activities of natural substances in human hepatocellular carcinoma[J]. Diseases, 2015, 3(4):260-281. DOI: 10.3390/diseases3040260. doi:10.3390/diseases3040260pmid:28943624
[24]	周珍, 刘少平, 周朗, 等. 黄芩素通过PI3K/AKT通路增强三氧化二砷对肝癌细胞的促凋亡作用[J]. 现代肿瘤医学, 2019, 27(10):1661-1668. DOI: 10.3969/j.issn.1672-4992.2019.10.002. doi:10.3969/j.issn.1672-4992.2019.10.002
[25]	Shen L, Zhang G, Lou Z, et al. Cryptotanshinone enhances the effect of arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated-STAT3 in vitro and in vivo[J]. BMC Complement Altern Med, 2017, 17(1):106. DOI: 10.1186/s12906-016-1548-4. doi:10.1186/s12906-016-1548-4

Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References25

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
[6]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke.Diagnostic value of serum TIM-3 in patients with liver cancer[J]. Journal of International Oncology, 2022, 49(9): 537-542.
[7]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng.Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer[J]. Journal of International Oncology, 2022, 49(10): 592-596.
[8]	Di Weihua, Zhao Xuemei.Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.
[9]	Han Baojun.Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of International Oncology, 2021, 48(7): 415-419.
[10]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang.Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245.
[11]	Xiong Lin, Zhang Xiuyun, Zhang Xiaoyu, Li Yue, Xu Ximing.IWR-1-endo affects the migration and proliferation of hepatocarcinoma cells by inhibiting the Wnt pathway[J]. Journal of International Oncology, 2021, 48(12): 711-715.
[12]	Liu Junguo, Zhang Jinjuan, Wang Yijun.Clinical application progress of variations in the technique of liver partition from ALPPS[J]. Journal of International Oncology, 2020, 47(8): 492-495.
[13]	Xin Ruiqiang, Song Xiaoping, Zhang Fan, Sun Ying, Wang Tao, Sun Wei.Mechanism of SUMO regulating XBP1 mediated endoplasmic reticulum stress on the progression of liver cancer[J]. Journal of International Oncology, 2020, 47(7): 397-403.
[14]	Su Wenzhen, Lin Yongjie, Wang Zhengyu, Liu Jisong.Clinical effect of local and systemic zoledronic acid in the treatment of giant cell tumor of bone[J]. Journal of International Oncology, 2020, 47(7): 409-413.
[15]	Jin Chenxing, Zhao Yi.Research progress of KRAS mutation in lung adenocarcinoma[J]. Journal of International Oncology, 2020, 47(3): 180-184.